- Home
- IRON vs PHR Comparison
IRON vs PHR Comparison
Compare IRON & PHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- PHR
- Stock Information
- Founded
- IRON 2017
- PHR 2005
- Country
- IRON United States
- PHR United States
- Employees
- IRON N/A
- PHR N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- PHR Business Services
- Sector
- IRON Health Care
- PHR Consumer Discretionary
- Exchange
- IRON Nasdaq
- PHR Nasdaq
- Market Cap
- IRON 1.4B
- PHR 1.5B
- IPO Year
- IRON N/A
- PHR 2019
- Fundamental
- Price
- IRON $51.61
- PHR $26.23
- Analyst Decision
- IRON Strong Buy
- PHR Strong Buy
- Analyst Count
- IRON 10
- PHR 12
- Target Price
- IRON $93.40
- PHR $31.50
- AVG Volume (30 Days)
- IRON 372.4K
- PHR 614.2K
- Earning Date
- IRON 08-07-2025
- PHR 05-28-2025
- Dividend Yield
- IRON N/A
- PHR N/A
- EPS Growth
- IRON N/A
- PHR N/A
- EPS
- IRON N/A
- PHR N/A
- Revenue
- IRON N/A
- PHR $434,532,000.00
- Revenue This Year
- IRON N/A
- PHR $14.74
- Revenue Next Year
- IRON N/A
- PHR $11.57
- P/E Ratio
- IRON N/A
- PHR N/A
- Revenue Growth
- IRON N/A
- PHR 16.29
- 52 Week Low
- IRON $30.82
- PHR $17.07
- 52 Week High
- IRON $68.73
- PHR $30.53
- Technical
- Relative Strength Index (RSI)
- IRON 56.99
- PHR 53.10
- Support Level
- IRON $48.87
- PHR $24.80
- Resistance Level
- IRON $54.13
- PHR $28.40
- Average True Range (ATR)
- IRON 2.31
- PHR 0.96
- MACD
- IRON 0.07
- PHR -0.06
- Stochastic Oscillator
- IRON 67.64
- PHR 52.15
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About PHR Phreesia Inc.
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.